Evidence map›Paper›PMID 26271341›Full record

Trial reportPathology oncology research : POR2016

Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma.

Julie A Theurer, William Stecho, John Yoo, Keith Kwan, Bret Wehrli, Vimla Harry, Morgan Black, Nicole Pinto, Eric Winquist, David Palma and 6 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Pathology oncology research : POR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Julie A TheurerDepartment of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine & Dentistry, Western University, 800 Commissioners Rd. E., London, ON, N6A 5W9, Canada. jtheurer@uwo.ca.
William StechoDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University, Dental Sciences Building, London, ON, N6A 5C1, Canada.
John YooDepartment of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine & Dentistry, Western University, 800 Commissioners Rd. E., London, ON, N6A 5W9, Canada.
Keith KwanDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University, Dental Sciences Building, London, ON, N6A 5C1, Canada.
Bret WehrliDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University, Dental Sciences Building, London, ON, N6A 5C1, Canada.
Vimla HarryDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University, Dental Sciences Building, London, ON, N6A 5C1, Canada.
Morgan BlackDepartment of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine & Dentistry, Western University, 800 Commissioners Rd. E., London, ON, N6A 5W9, Canada.
Nicole PintoDepartment of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine & Dentistry, Western University, 800 Commissioners Rd. E., London, ON, N6A 5W9, Canada.
Eric WinquistDepartment of Oncology, Western University, 790 Commissioners Rd. E., London, ON, N6A 5W9, Canada.
David PalmaLawson Health Research Institute, 750 Base Line Rd., London, ON, N6C 2R5, Canada.
Suzanne RichterDepartment of Oncology, Western University, 790 Commissioners Rd. E., London, ON, N6A 5W9, Canada.
John W BarrettDepartment of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine & Dentistry, Western University, 800 Commissioners Rd. E., London, ON, N6A 5W9, Canada.
S Danielle MacNeilDepartment of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine & Dentistry, Western University, 800 Commissioners Rd. E., London, ON, N6A 5W9, Canada.
Kevin FungDepartment of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine & Dentistry, Western University, 800 Commissioners Rd. E., London, ON, N6A 5W9, Canada.
Christopher J HowlettDepartment of Pathology and Laboratory Medicine, Schulich School of Medicine & Dentistry, Western University, Dental Sciences Building, London, ON, N6A 5C1, Canada.
Anthony C NicholsDepartment of Otolaryngology - Head and Neck Surgery, Schulich School of Medicine & Dentistry, Western University, 800 Commissioners Rd. E., London, ON, N6A 5W9, Canada.
Western University · CALondon Health Sciences Centre · CALawson Health Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PIK3CA is the only frequently-mutated, directly druggable oncogene in head and neck squamous cell carcinoma (HNSCC). However, it is unclear if a molecularly-driven intervention trial can be launched successfully, particularly within a single-institution setting secondary to the infrastructure necessary for mutation detection, mutation prevalence, and patient willingness to participate. This study aimed to evaluate 1) local frequency of PIK3CA activating mutations in HNSCC, 2) timeliness of our mutation-profiling clinical pathway, and 3) patients' willingness to enroll in a novel neoadjuvant drug trial. Tissue biopsies of 25 consecutive cases of HNSCC were tested for activating PIK3CA mutations at three mutational hotspots by real-time polymerase chain reaction. Mutations prevalence and number of working days accrued in determining PIK3CA mutational status were calculated. In addition, 30 HNSCC patients were surveyed prospectively regarding their willingness to participate in a hypothetical drug trial. Survey data were summarized descriptively. 4 of 25 (16 %) tumors harbored a PIK3CA activating mutation, including one at codon E542K, two at codon E545K/D, and one at codon H1047R. On average, this result was obtained in approximately 15 working days (range, 9-24 working days). The majority of patients surveyed (70 %) indicated their willingness to participate in a targeted PIK3CA trial. This study provides evidence that within a single institution, PIK3CA activating mutations can be detected with expected frequency, with sufficient timeliness and sufficient patient interest to mount a targeted intervention trial that may lead to improved tumor response in selected HNSCC patients.

Indexed as

Molecular Targeted TherapyAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Squamous CellClass I Phosphatidylinositol 3-KinasesFeasibility StudiesFemaleFollow-Up StudiesHead and Neck NeoplasmsHumansMaleMiddle AgedMutationNeoplasm StagingPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPIK3CA protein, humanBiomarkersFeasibility studyHead and neck squamous cell carcinomaPIK3CATargeted therapeutics

Identifiers

PMID26271341
OpenAlexW2468165760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.